- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05584631
IVIG vs SCIG in CIDP
August 10, 2023 updated by: Luigi Brunetti, Rutgers, The State University of New Jersey
The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration
Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight.
The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight.
Total (TBW), ideal (IBW), and adjusted (AdjBW) body weight-based dosing strategies are suggested, but these recommendations are based on expert opinion rather than high quality evidence.
The adoption of a specific strategy is highly variable depending on the clinician and/or institutional setting.
Recently, payors have also adopted strategies to reduce IgG therapy costs of by capping doses.
These recommendations are often based on the presumption that IgG distribution is limited to the vascular space.
While this assertion is logical, it does not account for changes adipose tissue may confer on target sites, nor does it account for the potential for adipose tissue to function serve as a metabolic sink or a source of inflammatory mediators.
The later would be especially important in patients receiving SCIG.
Several observational studies have evaluated IgG dosing in obese patients and have been the source of support for dosing strategies.
Many of these studies were not representative of specific populations, contained a wide variety of patients with different IgG indications, and had inadequate serum sampling.
More recently, the phase III randomized controlled PATH trial did not find a correlation with serum IgG concentrations and clinical endpoints.
However, it is important to note that the study was not designed to evaluate pharmacokinetic and pharmacodynamic endpoints.
There is also considerable interpatient variation in response; therefore, identification of patient characteristics that predict response or IgG change from baseline will be a useful tool to improve patient responses.
Our study will evaluate the influence of body composition and other patient characteristics may have on IgG exposure when given intravenously or subcutaneously.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Luigi Brunetti, PhD
- Phone Number: 2016385868
- Email: brunetti@pharmacy.rutgers.edu
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Recruiting
- Rutgers, The State University of New Jersey Clinical Research Center
-
Contact:
- Luigi Brunetti, PhD
- Phone Number: 908-595-2645
- Email: luigi.brunetti@rutgers.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients aged >18 years with a current diagnosis of CIDP (based on European Federation of Neurological sciences / Peripheral Nerve Society CIDP diagnostic criteria).
- 1:1 conversion of IVIG to SCIG (weekly dose conversion) must fall within 0.2-to-0.4 mg/kg dose for SCIG.
Exclusion Criteria:
- Patients receiving IVIG for indications other than CIDP will be excluded.
- Patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (CrCl < 50 mL/min) will be excluded
- Active malignancies
- Diabetes
- Myasthenia gravis
- Immunodeficiency
- Autoimmune disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravenous immune globulin G
Subjects will receive there current intravenous immune globulin dose.
|
Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.
Other Names:
|
Experimental: Subcutaneous immune globulin G
The dosage will be converted from the subject's current intravenous immune globulin G dosage 1:1 (gm per gm).
|
Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of drug half-life
Time Frame: Through study completion, an average of 4 weeks
|
Calculation of drug half-life based on data obtained from serum samples
|
Through study completion, an average of 4 weeks
|
Assessment of immune globulin G serum concentration after intravenous immune globulin G administration
Time Frame: Just before drug administration, immediately after drug administration, approximately days 7 and 14 post drug administration
|
Serum IgG concentration (including subtype) will be measured using a human IgG ELISA kit
|
Just before drug administration, immediately after drug administration, approximately days 7 and 14 post drug administration
|
Assessment of immune globulin G serum concentration after subcutaneous immune globulin G administration
Time Frame: Just before drug administration, immediately after drug administration, approximately days 2, 4 and 7 post drug administration
|
Serum IgG concentration (including subtype) will be measured using a human IgG ELISA kit
|
Just before drug administration, immediately after drug administration, approximately days 2, 4 and 7 post drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of grip strength
Time Frame: Baseline and just before administration of next immune globulin dose.
|
Grip strength will be measured using the handheld Martin Vigorimeter just before each dose of IgG is administered during the study period.
Subjects will be asked to squeeze the dynamometer as hard as possible with each of his or her hands in a standing position.
|
Baseline and just before administration of next immune globulin dose.
|
Assessment of muscle function
Time Frame: Baseline and just before administration of next immune globulin dose.
|
The Medical Research Council (MRC) system for testing and grading of muscle function aims to provide a standardized and objective way to assess muscle function.
It was originally introduced in 1943 and has a long history of use in neurology, rehabilitation and general medicine examinations.
Assessments of muscles are done bilaterally, meaning that for each muscle tested, the same muscle on the opposite side of the body is also tested.
The MRC sum score is finally calculated by adding the score of each individually assessed muscle.
The MRC score ranges from 0 - 30 with 0 as the worst outcome.
|
Baseline and just before administration of next immune globulin dose.
|
Assessment of patient disability
Time Frame: Baseline and just before administration of next immune globulin dose.
|
The Rasch Overall Disability scale (I-RODS) and the Inflammatory Neuropathy Cause and Treatment Sensory (INCAT) sum score disability scale will be completed before the infusion of IgG.
The I-RODS score can range from 0 to 48 with 0 representing the greatest disability.
The INCAT score ranges from 0 - 10 with 10 representing worse outcome.
|
Baseline and just before administration of next immune globulin dose.
|
Assessment of fatigue
Time Frame: Baseline and just before administration of next immune globulin dose.
|
Fatigue is a common patient concern in CIDP and the Rasch-built fatigue severity scale (R-FSS) will be completed before the infusion of IgG.
The R-FSS ranges from 9 to 63 with 63 being the worst score
|
Baseline and just before administration of next immune globulin dose.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Luigi Brunetti, PhD, Rutgers, The State University of New Jersey
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 11, 2022
Primary Completion (Estimated)
October 18, 2024
Study Completion (Estimated)
October 18, 2024
Study Registration Dates
First Submitted
October 10, 2022
First Submitted That Met QC Criteria
October 13, 2022
First Posted (Actual)
October 18, 2022
Study Record Updates
Last Update Posted (Actual)
August 14, 2023
Last Update Submitted That Met QC Criteria
August 10, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Disease Attributes
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Polyradiculoneuropathy
- Chronic Disease
- Polyneuropathies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Immunoglobulins
- Immunoglobulins, Intravenous
- gamma-Globulins
- Rho(D) Immune Globulin
- Immunoglobulin G
Other Study ID Numbers
- Pro2019001038
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Inflammatory Demyelinating Polyneuropathy
-
University of AarhusOdense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Aalborg University HospitalRecruitingCIDP - Chronic Inflammatory Demyelinating PolyneuropathyDenmark
-
Vera BrilUnknownChronic Inflammatory Demyelinating Polyneuropathy (CIDP)Canada
-
CSL BehringCompletedPolyradiculoneuropathy, Chronic Inflammatory Demyelinating | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)United States, Japan, Australia, Canada, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
University Hospital, BordeauxRecruitingChronic Inflammatory Demyelinating Polyneuropathy (CIDP)France
-
SanofiRecruitingChronic Inflammatory Demyelinating Polyradiculoneuropathy | Polyneuropathy, Inflammatory Demyelinating, ChronicUnited States
-
OctapharmaRecruitingPediatric Chronic Inflammatory Demyelinating PolyneuropathyUnited States
-
Centre Hospitalier Universitaire de Saint EtienneLaboratoire français de Fractionnement et de BiotechnologiesCompletedDemyelinating PolyneuropathyFrance
-
UCB Biopharma SRLNo longer availableChronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
CSL BehringRecruitingPediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)United States
-
argenxCompletedChronic Inflammatory Demyelinating Polyneuropathy (CIDP)United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Clinical Trials on Intravenous immune globulin G
-
Prometic Biotherapeutics, Inc.Atlantic Research GroupCompletedPrimary ImmunodeficiencyUnited States
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)Japan
-
Green Cross CorporationAtlantic Research GroupCompletedImmunologic Deficiency SyndromeUnited States, Canada
-
Ajou University School of MedicineUnknown
-
Biotest Pharmaceuticals CorporationCompletedLiver Cirrhosis | Hepatitis, Viral, Human | Hepatocellular Carcinoma | Hepatitis C Infection | VirusesUnited States
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)United States
-
Baxalta now part of ShireCompleted
-
Baxalta now part of ShireCompleted
-
Queen Saovabha Memorial InstituteCompleted
-
Inova Health Care ServicesCSL BehringWithdrawn